325 results on '"Kimby, Eva"'
Search Results
2. Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population‐based study
3. Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials
4. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
5. Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients
6. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
7. Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma.
8. Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma
9. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
10. Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy
11. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
12. The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas
13. Response Assessment in Waldenström’s Macroglobulinaemia
14. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
15. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
16. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group
17. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia
18. Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia
19. Figure S1-S8 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
20. Supplementary Tables S1-S2 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
21. Data from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
22. Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment
23. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies
24. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
25. Supplementary Materials and Methods from T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
26. Lack of reproducibility of histopathological features in MYC ‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium
27. Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden
28. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
29. Career development:A balance of opportunities and choices
30. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
31. Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma
32. Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study
33. Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data
34. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
35. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
36. Response Assessment in Waldenström’s Macroglobulinaemia
37. Survival by first-line treatment type and timing of progression among follicular lymphoma patients: A national population-based study in Sweden
38. Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data.
39. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non‐Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study
40. Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma
41. B-cell receptor stereotyped subsets and outcome for patients with chronic lymphocytic leukemia in the HOVON 68 trial
42. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)
43. Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden
44. Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial
45. Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma
46. Double Hit Lymphoma Diagnosis and Treatment in Europe—A Cross-Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG)
47. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non‐Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.
48. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)
49. Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial
50. The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.